Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia

Critical Care Medicine

Volumn 36, Issue 3, 2008, Pages 737-744

  Heyland, Daren K ^a   Dodek, Peter ^b   Muscedere, John ^a   Day, Andrew ^a   Cook, Deborah ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Antibiotics; Broad spectrum antimicrobials; Combination therapy; Empirical therapy; Outcomes; Randomized controlled trial; Ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ACINETOBACTER; ADULT; ARTICLE; ARTIFICIAL VENTILATION; CANADA; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITALIZATION; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; VENTILATOR ASSOCIATED PNEUMONIA; DRUG COMBINATION; MIDDLE AGED;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; THIENAMYCINS;

EID: 44449125270     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/01.CCM.0B013E31816203D6     Document Type: Article

References (23)

1. Heyland DK, Cook DJ, Griffith L, et al: The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. Am J Respir Crit Care Med 1999;159:1249-1256
2. Safdar N, Dexfulian C, Collard HR, et al: Clinical and economic consequences of ventilator-associated pneumonia. Crit Care Med 2005;33:2184-2193
3. Baker AM, Meredith JW, Chang M, et al: Bronchoscopically guided management of ventilator-associated pneumonia in trauma patients. J Bronchology 2003;10:7-16
4. Mathevon T, Souweine B, Tranore O, et al: ICU-acquired nosocomial infection: Impact of delay of adequate antibiotics treatment. Scand J Infect Dis 2002;34:831-835
5. Steinberg M, Aarts MW, Parkes R, et al: Canadian Critical Care Trials Group: Empiric antimicrobial therapy for suspected ICU-acquired infection: The AATIC pilot study. Intensive Care Med 2006;32: S113
6. Alvarez-Lerma F, for ICU-Acquired Pneumonia Study Group: Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996;22:387-394
7. Dupont H, Mentec H, Sollet JP, et al: Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001;27:355-362
8. Luna CM, Vujacich P, Niederman MS, et al: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111:676-685
9. Kollef MH, Ward S: The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998;113:412-420
10. Kollef MH, Sherman G, Ward S, et al: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-474
11. Trouillet JL, Chastre J, Vuagnat A, et al: Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157:531-539
12. Anonymous: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
13. Kollef M, Micek ST: Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 2005;33:1845-1853
14. Heyland DK, for the Canadian Critical Care Trials Group: A randomized trial of diagnostic techniques for suspected VAP. N Engl J Med 2006;355:2619-2630
15. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of diseases classification system. Crit Care Med 1985;13:818-829
16. Marshall JC, Cook DJ, Christou NV, et al: Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995;23:1638-1652
17. Ely EW, Bennett PA, Bowton DL, et al: Large scale implementation of a respiratory therapist-driven protocol for ventilator weaning. Am J Respir Crit Care Med 1999;159:439-446
18. Fagon JY, Chastre J, Wolff M, et al: Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: A randomized trial. Ann Intern Med 2000;132:621-630
19. Lan K K G, De Mets DL: Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-663
20. Neuhauser MM, Weinstein RA, Rydman R, et al: Antibiotic resistance among Gramnegative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 2003;289:885-888
21. Livermore D: Of pseudomonas, porins, pumps, and carbapenems. J Antimicrob Chemother 2001;47:247-250
22. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al: B lactam monotherapy versus B lactamaminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomized trials. BMJ 2004;328:668
23. Bliziotis IA, Samonis G, Vardakas KZ, et al: Effect of aminoglycoside and B-lactam combination therapy versus B-lactam monotherapy on the emergence of antimicrobial resistance: A meta-analysis of randomized, controlled trials. CID 2005;41:149-158